EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)
Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx
10 findings from 1 review
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes24 to 70 months · Mucositis (all grades)Mucositis all grades: not estimable due to high heterogeneity (P=0.0009; I2=86%) between subgroups (cetuximab; nimotuzumab) and within cetuximab (I2=93%); 1417 participants, 3 studies. Table 3, row 1.6 (Ang 2014;…3 studies · 1417 participantsGRADE not reported
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes24 to 70 months · Skin toxicity/acneiform rash (cetuximab, all grades)RR 6.56 [5.35, 8.03]2 studies · 1311 participantsGRADE not reported
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes24 to 70 months · Xerostomia (grades >=3)RR 1.36 [0.80, 2.31]2 studies · 1311 participantsGRADE not reported
Show 7 more findings
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes24 to 70 months · Skin toxicity/acneiform rash (nimotuzumab, grades >=3)RR 0.20 [0.01, 4.05]1 study · 92 participantsGRADE not reported
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes24 to 70 months · Skin toxicity/acneiform rash (nimotuzumab, all grades)RR 1.06 [0.85, 1.31]1 study · 92 participantsGRADE not reported
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes24 to 70 months · Dysphagia (all grades)RR 0.97 [0.92, 1.03]3 studies · 1403 participantsGRADE not reported
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes24 to 70 months · Skin toxicity/acneiform rash (cetuximab, grades >=3)RR 17.72 [8.33, 37.73]3 studies · 1403 participantsGRADE not reported
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes24 to 70 months · Dysphagia (grades >=3)RR 0.93 [0.83, 1.04]3 studies · 1403 participantsGRADE not reported
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes24 to 70 months · Mucositis (grades >=3)RR 1.20 [0.96, 1.51]4 studies · 1495 participantsGRADE not reported
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes24 to 70 months · Xerostomia (all grades)RR 0.97 [0.91, 1.04]3 studies · 1417 participantsGRADE not reported